No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.7x · 10Y median 0.5x · 72nd percentile · as of Sep 11, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-19T00:15:52.642Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Oscar Health, Inc. (OSCR) stock was $32.13 as of Sep 18, 2026, 4:00 PM EDT, up 0.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +68.7% · 3-year avg +70.8%/yr · 5-year avg +13.4%/yr
Oscar Health, Inc. operates as a health insurance provider across the United States.
Medical - Healthcare Plans · New York City, NY
Next Earnings Date
Nov 9, 2026
51 days away
EPS Estimate
-0.27
Revenue Est.
$4.70B
Last Quarter Results
EPS
$1.10
vs Estimate
$0.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OSCR | $8.33B | $32.13 | +0.47% | +68.72% | +13.36% | N/A | N/A |
| 2HSIC | $9.66B | $84.84 | -0.24% | +27.07% | +2.85% | +3.56% | vs OSCR |
| 3PODD | $9.74B | $140.60 | -0.67% | -60.98% | -14.94% | +12.38% | vs OSCR |
| 4GMED | $9.99B | $74.08 | -0.11% | +24.46% | -1.85% | +12.47% | vs OSCR |
| 5CHE | $6.59B | $504.06 | -0.38% | +13.30% | +2.02% | +14.57% | vs OSCR |
| 6BIO | $10.13B | $376.41 | -1.57% | +29.20% | -14.74% | +8.88% | vs OSCR |
4.06
$4.79B
vs Estimate
$4.73B
Consensus Rating
Based on 10 analysts
Average Price Target
$30.70
-4.5% downside
Low
$26.00
Current
$32.13
High
$39.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.25 | $-0.22 | $-0.20 | 6 |
| Quarter ending Dec 2026 | $-1.38 | $-1.24 | $-1.10 | 5 |
| Quarter ending Mar 2027 | $2.07 | $2.17 | $2.27 | 3 |
| Quarter ending Jun 2027 | $0.89 | $0.93 | $0.97 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.54 | $1.72 | $1.85 | 6 |
| FY 2027 | $1.45 | $1.90 | $2.39 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4.63B | $4.70B | $4.78B | 5 |
| Quarter ending Dec 2026 | $4.37B | $4.48B | $4.59B | 5 |
| Quarter ending Mar 2027 | $4.93B | $5.10B | $5.27B | 4 |
| Quarter ending Jun 2027 | $4.93B | $5.10B | $5.27B | 4 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $18.61B | $18.65B | $18.69B | 6 |
| FY 2027 | $19.39B | $20.26B | $21.15B | 6 |
